ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation
Introduction The ACCM/PALS guidelines address early correction of paediatric septic shock using conventional measures. In the evolution of these recommendations, indirect measures of the balance between systemic oxygen delivery and demands using central venous or superior vena cava oxygen saturation...
Gespeichert in:
Veröffentlicht in: | Intensive care medicine 2008-06, Vol.34 (6), p.1065-1075 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction
The ACCM/PALS guidelines address early correction of paediatric septic shock using conventional measures. In the evolution of these recommendations, indirect measures of the balance between systemic oxygen delivery and demands using central venous or superior vena cava oxygen saturation (ScvO
2
≥ 70%) in a goal-directed approach have been added. However, while these additional goal-directed endpoints are based on evidence-based adult studies, the extrapolation to the paediatric patient remains unvalidated.
Objective
The purpose of this study was to compare treatment according to ACCM/PALS guidelines, performed with and without ScvO
2
goal-directed therapy, on the morbidity and mortality rate of children with severe sepsis and septic shock.
Design, participants and interventions
Children and adolescents with severe sepsis or fluid-refractory septic shock were randomly assigned to ACCM/PALS with or without ScvO
2
goal-directed resuscitation.
Measurements
Twenty-eight-day mortality was the primary endpoint.
Results
Of the 102 enrolled patients, 51 received ACCM/PALS with ScvO
2
goal-directed therapy and 51 received ACCM/PALS without ScvO
2
goal-directed therapy. ScvO
2
goal-directed therapy resulted in less mortality (28-day mortality 11.8% vs. 39.2%,
p
= 0.002), and fewer new organ dysfunctions (
p
= 0.03). ScvO
2
goal-directed therapy resulted in more crystalloid (28 (20–40) vs. 5 (0–20) ml/kg,
p
|
---|---|
ISSN: | 0342-4642 1432-1238 |
DOI: | 10.1007/s00134-008-1085-9 |